# Vitamin D Deficiency

Use serum 25-hydroxyvitamin D to identify clinically meaningful deficiency, then distinguish low intake or sun exposure from malabsorption, CKD-related mineral disease, phosphate-wasting disorders, and toxicity-prone treatment settings before selecting replacement and monitoring calcium-phosphate physiology.

**Clinical question:** How should clinicians evaluate vitamin D deficiency, identify secondary causes, and safely direct replacement and monitoring?

Updated: 2026-08-24T18:28:32.708773+00:00

## What matters in practice
- Measure serum 25-hydroxyvitamin D rather than 1,25-dihydroxyvitamin D to assess nutritional vitamin D status; values below 10-12 ng/mL are associated with greatest concern for rickets or osteomalacia, while 20 ng/mL is a skeletal-health adequacy target used in selected guidance. [10][23][3]
- Interpret a low 25-hydroxyvitamin D level with calcium, phosphate, alkaline phosphatase, creatinine, and PTH when osteomalacia, hypocalcemia, hypophosphatemia, CKD-mineral bone disorder, or secondary hyperparathyroidism is suspected. [13][15][7]
- Low calcium with secondary hyperparathyroidism can drive renal phosphate wasting; low phosphate with inappropriately normal or low calcitriol instead suggests renal phosphate-wasting or FGF23-mediated disease rather than simple nutritional deficiency. [13]
- Avoid empiric vitamin D in hypercalcemia or hypervitaminosis D; stop vitamin D immediately if toxicity with hypercalcemia occurs and treat volume depletion with saline. [1]

## Confirm deficiency and identify mineral complications

Test when the result will change evaluation of skeletal, mineral, or high-risk disease.

Order serum 25-hydroxyvitamin D [25(OH)D] as the nutritional status marker. Serum 25(OH)D below 10 ng/mL has been associated with a higher prevalence of osteomalacia or rickets; the Institute of Medicine concluded that 20 ng/mL is adequate for skeletal health in healthy adults, and XLH guidance targets a 25(OH)D concentration above 20 ng/mL. Thresholds above this level remain clinically variable across laboratories and disease contexts. [10][3][24]

When deficiency may be clinically consequential, obtain total calcium with albumin, phosphate, alkaline phosphatase, creatinine/eGFR, and intact PTH. Vitamin D deficiency can produce hypocalcemia and hypophosphatemia, triggering secondary hyperparathyroidism; the resulting PTH elevation increases renal phosphate loss. [13][2]

Add fracture-directed imaging or metabolic bone evaluation when symptoms or fractures suggest defective mineralization. Adult osteomalacia is associated with fractures and pseudofractures, whereas rickets shows widened growth plates; these imaging patterns should prompt a search for malabsorption, renal phosphate loss, genetic disease, or impaired vitamin D activation rather than attribution to low sun exposure alone. [13]
- In cirrhosis, screen annually for micronutrient deficiencies including vitamin D; obtain DXA at diagnosis and periodically thereafter, particularly with cholestatic liver disease. [21]
- In CKD with secondary hyperparathyroidism, interpret PTH together with calcium, phosphate, and vitamin D because PTH assays have important intermethod and preanalytic variability. [7]

*Biochemical patterns that redirect the evaluation of low 25(OH)D. [13][15][7]*

| Pattern | Most useful discriminators | Next clinical direction |
| --- | --- | --- |
| Low 25(OH)D with elevated PTH and low calcium and/or low phosphate | Secondary hyperparathyroidism can cause renal phosphate wasting. [13] | Assess intake, sun exposure, malabsorption, liver disease, and medication or comorbidity contributors; replace nutritional vitamin D while following calcium and phosphate. [13][21] |
| Low phosphate with inappropriately normal or low calcitriol | Renal tubular phosphate loss or circulating phosphatonins suppress calcitriol formation; this differs from the expected compensatory pattern of vitamin D deficiency. [13] | Evaluate for inherited hypophosphatemic disease, renal tubular injury, or tumor-induced phosphate wasting. [13] |
| CKD stages 3-5 with PTH elevation | CKD-MBD assessment includes calcium, phosphate, PTH, alkaline phosphatase, and vitamin D; active vitamin D sterols can cause hypercalcemia, hyperphosphatemia, and excessive PTH suppression. [15] | Manage as CKD-MBD rather than treating the 25(OH)D value in isolation. [15][7] |
| Hypercalcemia during vitamin D exposure | Ergocalciferol is contraindicated in hypercalcemia and hypervitaminosis D. [1] | Stop vitamin D and evaluate for vitamin D toxicity and alternative causes of hypercalcemia. [1] |

## Use the laboratory pattern to separate nutritional deficiency from mimics

Low 25(OH)D is often contributory but does not exclude another mineralization disorder.

Insufficient oral or dermal vitamin D exposure is the most common cause of deficiency. In patients with a low 25(OH)D concentration and no major calcium-phosphate abnormality, prioritize a history of dietary intake, limited ultraviolet exposure, obesity, and factors limiting adherence; obesity may require several-fold higher supplementation doses to achieve and maintain a normal concentration. [24]

Malabsorption should move higher in the differential when low 25(OH)D coexists with persistent biochemical abnormalities despite oral replacement or with hepatobiliary, pancreatic, or gastrointestinal disease. Calcium malabsorption from these disorders can cause rickets or osteomalacia, and bariatric surgery—especially Roux-en-Y gastric bypass—is associated with vitamin D and other micronutrient deficiencies. [13][20]

Do not label all hypophosphatemic bone disease as nutritional vitamin D deficiency. In genetic or tumor-associated phosphate-wasting states, suppressed calcitriol production with an inappropriately normal or low circulating calcitriol concentration is a characteristic clue; renal tubular defects or damage are alternative causes of renal phosphate loss. [13]

Hypophosphatasia is a key exception when mineralization failure is accompanied by low rather than high alkaline phosphatase. This pattern reflects reduced activity of the bone alkaline phosphatase isoenzyme and pyrophosphate accumulation, which inhibits mineralization. [13]

### Secondary hyperparathyroidism

Vitamin D deficiency is a common cause of secondary hyperparathyroidism, particularly in older adults. In XLH patients with elevated PTH, evaluate both vitamin D status and dietary calcium intake; low urinary calcium excretion suggests calcium deprivation from low calcium intake and/or vitamin D deficiency. [2][3]
- In CKD, evaluate elevated PTH using the full CKD-MBD profile rather than a single PTH value; active vitamin D products have clinically important calcium and phosphate tradeoffs. [15][7]

*Etiologic branches in vitamin D-associated mineralization disorders. [13][20][21]*

| Branch | Clues that change the diagnosis | Action |
| --- | --- | --- |
| Nutritional deficiency | Low 25(OH)D without a competing phosphate-wasting or low-alkaline-phosphatase pattern. [10][13] | Correct intake or exposure deficit and reassess mineral indices when initially abnormal. [13] |
| Malabsorption or post-bariatric state | Hepatobiliary, pancreatic, gastrointestinal disease, or Roux-en-Y gastric bypass with micronutrient deficiency. [13][20] | Address the underlying absorptive disorder and ensure ongoing micronutrient surveillance. [20] |
| Cirrhosis or cholestatic liver disease | Cirrhosis with malnutrition risk; cholestatic liver disease increases concern for low bone density. [21] | Screen vitamin D and other micronutrients annually; obtain DXA at diagnosis and periodically as indicated. [21] |
| Phosphate-wasting disease | Hypophosphatemia with inappropriately normal or low calcitriol. [13] | Investigate renal tubular, inherited, and tumor-associated causes before using a nutritional-deficiency framework. [13] |

## Replace native vitamin D when the clinical context supports deficiency

Select native versus active vitamin D according to the underlying disorder and calcium-phosphate risk.

Use native vitamin D—cholecalciferol or ergocalciferol—to correct nutritional deficiency and to maintain 25(OH)D above 20 ng/mL in the XLH guidance context. In adults with XLH receiving oral phosphate, combine phosphate supplements with active vitamin D rather than native vitamin D alone; adults require substantially lower active vitamin D and phosphate doses than children. [3]

Do not extrapolate replacement regimens across disease states. A published loading strategy used vitamin D 20,000-40,000 IU once weekly followed by 4,000-6,000 IU daily maintenance, but dosing must be individualized to the indication, baseline concentration, absorption, renal function, calcium concentration, and concurrent active vitamin D or phosphate therapy. [11]

Ergocalciferol labeling describes a narrow therapeutic-to-toxic range and contraindicates use in hypercalcemia, malabsorption syndrome, abnormal sensitivity to vitamin D toxicity, and hypervitaminosis D. The labeled indications include hypoparathyroidism, vitamin D-resistant rickets, and familial hypophosphatemia; the high doses described for these indications require close medical supervision and laboratory monitoring. [1]
- In CKD stages 3-5, nutritional vitamin D and calcitriol have been compared for CKD-MBD, but active vitamin D sterols can cause hypercalcemia, hyperphosphatemia, and oversuppression of PTH. [15]
- For vitamin D toxicity with hypercalcemia, immediately stop vitamin D, provide a low-calcium diet and generous fluids; hypercalcemic crisis with dehydration, stupor, coma, or azotemia requires IV saline and may require additional directed measures. [1]

### Monitoring after treatment begins

Recheck the abnormal parameters that drove treatment rather than relying only on symptoms. For deficiency associated with secondary hyperparathyroidism or mineral abnormalities, follow 25(OH)D with calcium, phosphate, and PTH; in CKD, include alkaline phosphatase and interpret PTH in light of assay variability. [7][15]
- Escalate evaluation when calcium rises, phosphate becomes elevated in CKD or active vitamin D use, PTH is excessively suppressed, or a low 25(OH)D concentration persists despite an adherent replacement plan. [15][1]

*Treatment selection and safety checkpoints. [1][3][11][15]*

| Clinical setting | Treatment direction | Safety checkpoint |
| --- | --- | --- |
| Nutritional deficiency | Use native cholecalciferol or ergocalciferol; a reported regimen used 20,000-40,000 IU weekly followed by 4,000-6,000 IU daily. [11] | Individualize for baseline level, absorption, calcium, renal function, and co-therapies. [11] |
| XLH with oral phosphate | Use oral phosphate together with active vitamin D; assure adequate calcium intake and maintain 25(OH)D above 20 ng/mL. [3] | Use lower active vitamin D and phosphate doses in adults than in children. [3] |
| CKD-MBD | Assess nutritional vitamin D within calcium-phosphate-PTH-alkaline phosphatase management. [15] | Active vitamin D carries risks of hypercalcemia, hyperphosphatemia, and PTH oversuppression. [15] |
| Vitamin D-associated hypercalcemia | Withdraw vitamin D immediately and hydrate; use IV saline for hypercalcemic crisis. [1] | Ergocalciferol is contraindicated in hypercalcemia and hypervitaminosis D. [1] |

## Escalate atypical mineral patterns rather than repeatedly increasing replacement

Persistent or discordant biochemical findings warrant etiologic reassessment.

Refer for endocrine, nephrology, or metabolic bone evaluation when hypophosphatemia persists, calcitriol is inappropriately normal or low, alkaline phosphatase is low despite suspected osteomalacia, or fractures/pseudofractures occur. These findings raise renal phosphate-wasting disorders, FGF23-mediated disease, hypophosphatasia, or impaired vitamin D bioactivation or resistance. [13]

In CKD with secondary hyperparathyroidism, involve nephrology when calcium, phosphate, PTH, and alkaline phosphatase cannot be interpreted or controlled as a coherent CKD-MBD pattern, particularly if active vitamin D therapy is being considered or produces hypercalcemia, hyperphosphatemia, or PTH oversuppression. [15][7]

## References
1. <br/> <br/> Vitamin D <br/> <br/> <br/> <br/> (Ergocalciferol Capsules, USP) — nctr-crs.fda.gov — https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/c538ac91-2507-4f42-8f7a-013510539b30/spl-doc?hl=
2. Hyperparathyroidism — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140673609605079/abstract
3. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia | Nature Reviews Nephrology — www.nature.com — https://www.nature.com/articles/s41581-024-00926-x
4. Vitamin D and spinal cord injury: should we care? | Spinal Cord — www.nature.com — https://www.nature.com/articles/sc2016131
5. Screening for Vitamin D Deficiency: A Systematic Review ... — www.acpjournals.org — https://www.acpjournals.org/doi/full/10.7326/M14-1659?download=true&journalCode=aim
6. Obtaining Vitamin D Levels in Children With Fractures Improves ... — journals.lww.com — https://journals.lww.com/pedorthopaedics/fulltext/2019/07000/obtaining_vitamin_d_levels_in_children_with.11.aspx?Ppt=Article%7Cpedorthopaedics%3A2019%3A07000%3A00011%7C10.1097%2Fbpo.0000000000001363%7C
7. Treatment of secondary hyperparathyroidism in... : Nephrology Dialysis Transplantation — journals.lww.com — https://journals.lww.com/00005884-202306000-00009
8. The High Prevalence of Hypovitaminosis D in China — journals.lww.com — https://journals.lww.com/md-journal/_layouts/15/oaks.journals/downloadpdf.aspx?an=00005792-201502040-00015
9. Trends of Elevated Parathormone Serum Titers in... — journals.lww.com — https://journals.lww.com/sjkd/fulltext/2014/25060/trends_of_elevated_parathormone_serum_titers_in.5.aspx
10. Ergocalciferol - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/neuroscience/ergocalciferol
11. Use of a Loading Dose of Vitamin D for Treatment of Vitamin D ... — aspenjournals.onlinelibrary.wiley.com — https://aspenjournals.onlinelibrary.wiley.com/doi/10.1177/0148607115625220
12. Vitamin D deficiency and supplementation in patients with ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/cam4.1166
13. Rickets and osteomalacia - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1357303906002891
14. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: A double-blind, multicenter, randomized study - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S027263860150339X
15. Ergocalciferol versus calcitriol for controlling chronic kidney disease mineral bone disorder in stage 3 to 5 CKD: A randomized controlled trial - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0014299916304496
16. 4. Comprehensive Medical Evaluation and Assessment of ... — diabetesjournals.org — https://diabetesjournals.org/care/article/47/Supplement_1/S52/153956/4-Comprehensive-Medical-Evaluation-and-Assessment
17. Nutrition Therapy for Pregnancy, Lactation, and Diabetes — diabetesjournals.org — https://diabetesjournals.org/books/book/44/chapter/4950692/Nutrition-Therapy-for-Pregnancy-Lactation-and
18. dc26s008.pdf - American Diabetes Association — diabetesjournals.org — https://diabetesjournals.org/care/article-pdf/49/Supplement_1/S166/848839/dc26s008.pdf
19. Researching asthma across the ages: Insights from the ... — www.jacionline.org — https://www.jacionline.org/article/S0091-6749(13)01639-4/pdf
20. The importance of nutrition in pregnancy and lactation: lifelong consequences — www.ajog.org — https://www.ajog.org/article/S0002-9378(21)02728-9/fulltext
21. Back to Basics: Outpatient Management of Cirrhosis — www.aasld.org — https://www.aasld.org/liver-fellow-network/core-series/back-basics/back-basics-outpatient-management-cirrhosis
22. Researching asthma across the ages: Insights from ... — www.jacionline.org — https://www.jacionline.org/article/S0091-6749(13)01639-4/fulltext
23. WHO EMRO - High prevalence of vitamin D deficiency in the sunny Eastern region of Saudi Arabia: a hospital-based study — www.emro.who.int — https://www.emro.who.int/emhj-volume-17/issue-4/article9.html
24. Vitamin D supplementation: Pearls for practicing clinicians — www.ccjm.org — https://www.ccjm.org/content/89/3/154

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.